[ad_1]
FILE PHOTO: Small bottles labeled with a “Vaccine COVID-19” sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
BENGALURU (Reuters) – Indian biotech firm Panacea Biotec Ltd said on Wednesday it would partner with U.S.-based Refana Inc to make a potential vaccine for COVID-19.
The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges. (bit.ly/3dPPZQM)
Panacea’s shares jumped 20% in morning trading on India’s National Stock Exchange after the news.
Reporting by Sachin Ravikumar; Editing by Shailesh Kuber
[ad_2]
Source link